PL345513A1 - Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway, and inhibitors of lipid metabolism - Google Patents

Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway, and inhibitors of lipid metabolism

Info

Publication number
PL345513A1
PL345513A1 PL99345513A PL34551399A PL345513A1 PL 345513 A1 PL345513 A1 PL 345513A1 PL 99345513 A PL99345513 A PL 99345513A PL 34551399 A PL34551399 A PL 34551399A PL 345513 A1 PL345513 A1 PL 345513A1
Authority
PL
Poland
Prior art keywords
methylerythrose
inhibitors
inhibit
active compounds
lipid metabolism
Prior art date
Application number
PL99345513A
Other languages
English (en)
Inventor
Hassan Jomaa
Original Assignee
Hassan Jomaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19828097A external-priority patent/DE19828097A1/de
Application filed by Hassan Jomaa filed Critical Hassan Jomaa
Publication of PL345513A1 publication Critical patent/PL345513A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
PL99345513A 1998-06-24 1999-06-23 Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway, and inhibitors of lipid metabolism PL345513A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19828097A DE19828097A1 (de) 1998-06-24 1998-06-24 Kombinationspräparat von Aminohydrocarbylphosphonsäurederivaten und Hemmern des Fettstoffwechsels
DE19843279 1998-09-22
PCT/EP1999/004360 WO1999066875A2 (de) 1998-06-24 1999-06-23 Kombinationspräparat von antiinfektiös wirkenden verbindungen, die den 2-c-methylerythrose-4-stoffwechselweg hemmen, und hemmern des fettstoffwechsels

Publications (1)

Publication Number Publication Date
PL345513A1 true PL345513A1 (en) 2001-12-17

Family

ID=26047010

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99345513A PL345513A1 (en) 1998-06-24 1999-06-23 Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway, and inhibitors of lipid metabolism

Country Status (10)

Country Link
EP (1) EP1100510A2 (de)
JP (1) JP2002518418A (de)
CN (1) CN1348374A (de)
AU (1) AU752714B2 (de)
CA (1) CA2334645A1 (de)
IL (1) IL139965A0 (de)
PL (1) PL345513A1 (de)
SK (1) SK19612000A3 (de)
TR (1) TR200003783T2 (de)
WO (1) WO1999066875A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2630341C (en) 1998-04-14 2011-07-26 Kyowa Hakko Kogyo Co., Ltd. Process for producing isoprenoid compounds by microorganisms
CN115708511A (zh) * 2014-02-23 2023-02-24 Fmc有限公司 3-异噁唑烷酮化合物作为选择性除草剂的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330529A (en) * 1978-02-15 1982-05-18 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
JPS6064991A (ja) * 1983-09-17 1985-04-13 Fujisawa Pharmaceut Co Ltd セファレキシン・ホスミドマイシン塩およびその製造法
US4846872A (en) * 1986-08-11 1989-07-11 Fujisawa Pharmaceutical Co., Ltd. Herbicide
JPH05163150A (ja) * 1991-05-13 1993-06-29 E R Squibb & Sons Inc アテローム性動脈硬化症の抑制・治療剤
ATE129407T1 (de) * 1991-10-11 1995-11-15 Squibb & Sons Inc Verwendung von biphosphonaten zur herstellung eines arzneimittels zur blockierung neoplastischer zelltransformationen die durch ras-oncogene verursacht werden.

Also Published As

Publication number Publication date
SK19612000A3 (sk) 2001-08-06
AU752714B2 (en) 2002-09-26
WO1999066875A3 (de) 2000-09-14
CA2334645A1 (en) 1999-12-29
EP1100510A2 (de) 2001-05-23
JP2002518418A (ja) 2002-06-25
AU4615599A (en) 2000-01-10
WO1999066875A2 (de) 1999-12-29
CN1348374A (zh) 2002-05-08
TR200003783T2 (tr) 2001-06-21
IL139965A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
HUP0103707A3 (en) Formulation of stable oxalyplatinum solution
HK1035194A1 (en) Novel pyridazine derivatives and drugs containing the same as the active ingredient
AU4217499A (en) Composition having therapeutic and/or nutritionally active substituent
GB9823101D0 (en) Pharmaceutically active compounds
HUP0105089A3 (en) Compositions containing the active ingredient in form dispersible phospholipid stabilized microparticles
EP1048673A4 (de) Inhibitor der neo-vaskularisierung, der als aktiven wirkstoff dienogest enthält
IL123232A0 (en) Medicament for inhibiting glucose metabolism deterioration
EP1195165A4 (de) Fibrose inhibitore die als aktiven bestandteil sphingosin-a-phosphat oder dessen rezeptoragonisten enthalten
HK1049798B (zh) 固體類脂製劑
IL139321A0 (en) Methods and compositions for modulating lipid metabolism
AU2001234114A1 (en) Drugs containing combined active ingredients
GB9823102D0 (en) Pharmaceutically active compounds
NO20011459D0 (no) Gener i biosyntesereaksjonsveien til 1-desoksy-D-xylulose
AU3445699A (en) Microbial preparation of substances from aromatic metabolism/iii
AU752953C (en) Adding pharmaceutically active compounds to substrates
PL349393A1 (en) Sulphonyloxazolamines as therapeutic active ingredients
AU2002328402A1 (en) Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient
PL345513A1 (en) Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway, and inhibitors of lipid metabolism
AU2001231053A1 (en) Lipid metabolism enzymes
GB2343844A8 (en) Topical therapeutic composition comprising an enzyme
AU1558700A (en) Combinations of active ingredients
AU2001245397A1 (en) Lipid metabolism enzymes
AU2001261424A1 (en) Lipid metabolism enzymes
AU8528398A (en) The structure of the shoe
AU2002361078A1 (en) Markers for sugar/lipid metabolic disorders and utilization thereof